Sequent Scientific Limited (SEQUENT.BO)
- Previous Close
179.90 - Open
180.85 - Bid 180.10 x --
- Ask --
- Day's Range
177.90 - 185.20 - 52 Week Range
91.85 - 240.90 - Volume
109,022 - Avg. Volume
64,215 - Market Cap (intraday)
45.005B - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
211.88 - EPS (TTM)
0.85 - Earnings Date Aug 12, 2025 - Aug 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 8, 2021
- 1y Target Est
--
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products. The company was formerly known as PI Drugs & Pharmaceuticals Ltd. and changed its name to Sequent Scientific Limited in October 2009. The company was incorporated in 1985 and is headquartered in Mumbai, India. Sequent Scientific Limited is a subsidiary of CA Harbor Investments.
www.sequent.in1,195
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SEQUENT.BO
View MorePerformance Overview: SEQUENT.BO
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SEQUENT.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SEQUENT.BO
View MoreValuation Measures
Market Cap
45.01B
Enterprise Value
49.12B
Trailing P/E
211.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.99
Price/Book (mrq)
6.39
Enterprise Value/Revenue
3.17
Enterprise Value/EBITDA
28.64
Financial Highlights
Profitability and Income Statement
Profit Margin
0.77%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
15.11B
Net Income Avi to Common (ttm)
116.51M
Diluted EPS (ttm)
0.85
Balance Sheet and Cash Flow
Total Cash (mrq)
742.6M
Total Debt/Equity (mrq)
65.94%
Levered Free Cash Flow (ttm)
--